Access to diabetes care for children and young people: Pharma companies’ current actions and…
A recently released report from Access to Medicine Foundation highlights that children and young people living in low-and…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Category
Latest Updates
Data cleaning and harmonisation: A catalyst for innovation
Messy data remains a persistent challenge in modern drug discovery. The complementary processes of data cleaning and data…
Trump’s move to transform US pharma manufacturing raises doubts over its effectiveness: GlobalData
GlobalData analysts highlight uncertainty around new FDA directives as pharma giants ramp up US-based manufacturing investments…
OneSource Specialty Pharma’s Bangalore facility maintains US FDA compliance with VAI classification
US FDA concludes inspection of OneSource’s flagship site with Voluntary Action Indicated status, confirming regulatory adherence…
Cadila Pharmaceuticals launches Biscado (Bisoprolol) for cardiovascular disease management in India
Biscado enters India’s beta-blocker therapy space, addressing the growing burden of heart disease with clinically supported…
CII Telangana to host “Pillars of Protection”conference on pharma and chemical safety
Hyderabad to host industry-wide dialogue on safety, compliance, and risk management in pharma and chemical manufacturing on 25th…
Pharma sector sees $6.96 billion in global deal activity in May 2025, led by GSK, Shionogi, and Eli…
M&A and venture capital deals in the global healthcare sector declined from the 12-month average, with three transactions…
Lupin receives tentative US FDA approval for Oxcarbazepine ER tablets
Oxcarbazepine extended-release tablets to be manufactured at Lupin’s Nagpur facility for US market
Supriya Lifescience’s Saloni Wagh and Shivani Wagh named in 2025 Candere Hurun India Women Leaders…
Leadership of Saloni Wagh and Shivani Wagh recognised as Supriya Lifescience posts highest-ever revenue in FY25
PureTech’s LYT-100 holds potential to expand treatment options for idiopathic pulmonary fibrosis:…
As current IPF treatments face adoption and efficacy challenges, GlobalData highlights LYT-100’s potential to address unmet needs…
ASPA commissions 2nd edition of counterfeiting report ahead of World Anti-Counterfeiting Day
The ASPA–CRISIL 2025 report will assess counterfeiting risks across key sectors in India and offer data-driven insights for brand…
Renewables to account for over half of Brazil’s annual power generation in 2035, forecasts…
Government policies, market liberalisation, and project development expected to accelerate Brazil’s shift from hydropower…
Santosh Mahil appointed CEO of Sekhmet Pharmaventures
Mahil to lead India-based API investment platform backed by PAG, CX Partners, and Samara Capital
Servier India launches IDH1-targeted therapy Ivosidenib for AML and Cholangiocarcinoma
CDSCO approves Servier’s Ivosidenib for treatment of AML and Cholangiocarcinoma patients with IDH1 mutation
Atopic dermatitis market to reach $22.4 billion in 7MM by 2033, forecasts GlobalData
Projected market growth driven by expanded treatment options, novel therapies, and rising diagnosed prevalence across major global…
Alvotech and Dr Reddy’s Laboratories partner to develop biosimilar for Keytruda targeting global…
Collaboration aims to accelerate development and commercialisation of pembrolizumab biosimilar, expanding access to cancer…
Shorter immunotherapy duration for advanced melanoma shows comparable disease control in UK DANTE…
UK-led phase III trial reports similar disease control at 12 months versus two years of immunotherapy for inoperable late-stage…
PLUSS Advanced Technologies and Ecodome Logistics unite to build India’s greenest, most reliable…
Partnership aims to reduce vaccine spoilage, cut carbon emissions, and improve temperature control in pharma logistics across…
EyePoint’s Duravyu holds potential to become new treatment option for wAMD: GlobalData
Sustained-release implant Duravyu may reduce treatment burden in wet AMD patients while maintaining efficacy and durability
Gland Pharma receives USFDA approval for Angiotensin II Acetate injection
Gland Pharma secures 180-day exclusivity for Angiotensin II Acetate Injection following USFDA approval